A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

Haematologica

Volumn 100, Issue 3, 2015, Pages 357-362

  Chen, Robert ^a   Frankel, Paul ^a   Popplewell, Leslie ^a   Siddiqi, Tanya ^a   Ruel, Nora ^a   Rotter, Arnold ^a   Thomas, Sandra H ^a   Mott, Michelle ^a   Nathwani, Nitya ^a   Htut, Myo ^a   Nademanee, Auayporn ^a   Forman, Stephen J ^a   Kirschbaum, Mark ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 6; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; B CELL LYMPHOMA; BONE MARROW BIOPSY; CHILL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FAINTNESS; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOXIA; KIDNEY INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RECURRENT DISEASE; SURVIVAL ANALYSIS; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXAMIC ACIDS; INJECTIONS, INTRAVENOUS; LYMPHOMA, B-CELL, MARGINAL ZONE; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOPENIA; MALE; MIDDLE AGED; RECURRENCE; RITUXIMAB; SURVIVAL ANALYSIS; THROMBOSIS;

EID: 84924699411     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.117473     Document Type: Article

References (21)

1. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett. 2009;280(2):145-153.
2. Frew AJ, Johnstone RW, Bolden JE. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett. 2009;280(2):125-133.
3. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood. 2000;96(12):3847-3856.
4. Kirschbaum M, Frankel P, Popplewell L, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non- Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29(9):1198-1203.
5. Ogura M, Ando K, Suzuki T, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol. 2014;165(6):768-776.
6. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97(1):101-106.
7. Martinelli G, Hsu Schmitz S-F, Utiger U, et al. Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single- Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. J Clin Oncol. 2010;28(29):4480-4484.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833.
9. Shi W, Han X, Yao J, Yang J, Shi Y. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leuk Res. 2012;36(6):749-755
10. Zhao WL, Wang L, Liu YH, et al. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol. 2007; 35(12):1801-1811
11. Li N, Zhao D, Kirschbaum M, et al. HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci USA. 2008; 105(12):4796-4801.
12. Cheson BD. The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am. 2007;21(5):841-854.
13. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4): 1244-1253.
14. Epron G, Ame-Thomas P, Le Priol J, et al. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012;26(1):139-148.
15. Harrison SJ, Hsu AK, Neeson P, et al. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant. Leuk Lymphoma. 2014; 55(5):1053-1060.
16. Kretzner L, Scuto A, Dino PM, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res. 2011; 71(11):3912-3920.
17. Emadali A, Rousseaux S, Bruder-Costa J, et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med. 2013;5(8):1180-1195.
18. Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol. 2009;27(32):5404-5409.
19. de Vos S, Goy A, Dakhil SR, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol. 2009;27(30):5023-5030.
20. Fowler NH, Advani RH, Sharman J, et al. The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma. ASH Annual Meeting Abstracts. 2012; 120:156.
21. Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008-1018.